Skip to Main Content

Immunology Track

Immunology Track Leadership

Faculty

  • Professor of Dermatology, Pathology, and Immunobiology; Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center; Director, Yale Center for Immuno-Oncology; Director, Yale SPORE in Skin Cancer

    Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Genomics, Genetics and Epigenetics Research Program of Yale Cancer Center, Contact PI of the Yale SPORE in Skin Cancer, Inaugural Director of the Yale Center for Immuno-Oncology, Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.

    In his research, Dr. Bosenberg studies the genetics and cellular changes that result in melanoma, the leading cause of skin cancer deaths. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new melanoma therapies, and how the immune system can be stimulated to fight melanoma. He works to translate basic scientific findings into improvements in melanoma diagnosis and therapy. He has published over 100 peer-reviewed articles, is a member of the Yale Cancer Center Executive Committee, and is a faculty member of the Raymond and Beverly Sackler Institute for Biological, Physical, and Engineering Sciences.

    Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

  • Assistant Professor

    Grace Chen received her undergraduate training in the College of Chemistry at UC Berkeley. She attended Harvard University for her PhD where she worked in David Liu's laboratory to discover and characterize novel RNA modifications. Her postdoctoral research was at Stanford University in Howard Chang's group, where she investigated circular RNA immunity. Grace Chen joined Yale University as a faculty in the Department of Immunobiology in 2019. Her research focuses on the functions and regulations of circular RNAs and RNA modifications in health and disease.

  • United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology); Co-Leader, Cancer Immunology, Yale Cancer Center

    Dr. Lieping Chen is United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Medicine (Medical Oncology) and Dermatology in Yale School of Medicine. He earned his medical degree from Fujian Medical College in Fuzhou, China. After clinical and research trainings in immunology and oncology in Fujian Union Hospital and Beijing Union Medical College, he got a PhD in Pathology from Drexel University in Philadelphia, Pennsylvania and did a postdoctoral fellowship in the University of Washington in Seattle. He worked as a research scientist in cancer and immunology discovery group in Bristol-Myers Squibb/Oncogen in Seattle from 1989-1997 before he moved to Mayo Clinic in Rochester, Minnesota as an Immunology Professor and Consultant from 1997-2004. He was Professor of Oncology and Dermatology at Johns Hopkins University School of Medicine in Baltimore, Maryland for 7 years and joined Yale since 2010.

    Dr. Chen has published more than 350 research articles, reviews and book chapters and edited two books. His work in discovery of the PD-1/PD-L1 pathway for cancer immunotherapy was cited as the #1 breakthrough of the years by Science magazine 2013. He is a member of U.S. National Academy of Sciences and a Fellow of American Association for Cancer Research.

  • Associate Professor

    Sidi Chen joined the Yale Faculty in 2015 in the Department of Genetics, Systems Biology Institute, and Yale Cancer Center. His research focuses on providing a global understanding of biological systems and development of novel breakthrough therapeutics. Chen developed and applied genome editing and high-throughput screening technologies, precision CRISPR-based in vivo models of cancer, global mapping of functional drivers of cancer oncogenesis and metastasis. He is leading a research group to seek global understandings of the molecular and cellular factors controlling disease progression and immunity. His group continuously invents versatile systems that enable rapid identification of novel targets and development of new modalities of cancer immunotherapy, cell therapy and gene therapy. His goal is to uncover novel insights in cancer and various other immunological diseases and develop next generation therapeutics. 

    Dr. Chen received a number of national and international awards including the Pershing Square Sohn Prize, DoD Era of Hope Scholar, NIH Director’s New Innovator Award,  Blavatnik Innovator Award, Yale Cancer Center Basic Science Research Prize, AACR NextGen Award for Transformative Cancer Research, Ludwig Foundation Award, Damon Runyon Cancer Research Fellow, Dale Frey Award for Breakthrough Scientists, TMKF Innovative/Translation Cancer Research Award, BCA Exceptional Research Grant Award, MRA Young Investigator Award, V Scholar, Bohmfalk Scholar, Ludwig Family Foundation Award, St. Baldrick’s Foundation Award, CRI Clinic & Laboratory Integration Program (CLIP), MIT Technology Review Top 35 Innovators (Regional), and Sontag Foundation Distinguished Scientist Award.

  • Paul B. Beeson Professor of Medicine (Rheumatology) and Professor of Immunobiology; Paul B. Beeson Professor of Medicine; Program Director, Investigative Medicine

    Dr. Joseph Craft is Paul B. Beeson Professor of Medicine and Professor of Immunobiology at the Yale School of Medicine, and past chief of the Section of Rheumatology at Yale. He received his degrees in chemistry as a Phi Beta Kappa graduate of University of North Carolina at Chapel Hill and in medicine as an Alpha Omega Alpha graduate of the University of North Carolina School of Medicine. Dr. Craft did postgraduate training in internal medicine and in rheumatology and immunology at Yale, and has been on the faculty at that institution since 1985. At Yale, he teaches undergraduate, graduate, and medical students. He directs a research laboratory devoted to understanding the immune response to pathogens and vaccines, and dissecting and treating autoimmune diseases, such as systemic lupus erythematosus, with a primary focus upon the differentiation, metabolism, and function and regulation of T cells that promote B cell maturation in secondary lymphoid organs. His research has been continually supported by the National Institutes of Health since 1985, and he is a two-time R37 (MERIT) Awardee. He has been a primary mentor for over 20 postdoctoral fellows and for 21 PhD and MD/PhD graduate students, including 7 graduate students currently in his lab. Dr. Craft is Director of the Investigative Medicine Program at Yale, a unique program designed to provide Ph.D. training for physicians, and in his capacity as Director of the program and its Director of Graduate Studies, has supervised training of over 50 Investigative Medicine PhD students. Dr. Craft is recipient of the Bohmfalk Teaching Prize at Yale School of Medicine for outstanding teaching in the basic sciences. He is an elected Fellow of the American Association for the Advancement of Science, and an elected member of the American Society for Clinical Investigation and the Kunkel Society. Dr. Craft also is a member of the Board of Lupus Therapeutics of the Lupus Research Alliance, devoted to initiating novel therapeutic trials in lupus, and past Chair of the Board of Scientific Counselors at the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS). He is former chair of the Immunological Sciences (now HAI) and current member of the Arthritis, Connective Tissue and Skin Diseases (ACTS) standing study sections at NIH, past chair of the Scientific Advisory Board of the Alliance for Lupus Research, and a former Pew Scholar in the Biomedical Sciences and Kirkland Scholar. He is co-founder of L2Diagnostics, a company in New Haven, CT, formed in partnership with Yale University and devoted to discovery of new diagnostics and therapeutic targets for immunological and infectious diseases, and is currently a member of its Board of Directors.

  • Associate Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine) and of Microbial Pathogenesis; Director, Center for Pulmonary Infection Research and Treatment (CPIRT)

    Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Associate Professor at Yale University in the same department. He is also the founding director for the Center for Pulmonary Infection Research and Treatment (CPIRT). www.cpirt.yale.edu. His laboratory is interested in studying the role of respiratory infection in the pathogenesis of acute and chronic lung diseases. Specifically, his work focuses on how lung infection contribute to inflammation, injury and tissue repair in the lung. This has allowed the lab to carefully study the molecular and cellular responses of several novel mediators in the lung.

    His laboratory focuses on two main research programs. (1) Studying novel immune regulators in the lung during respiratory infections. (2) Studying the effects of cigarette smoke (CS) exposure in the pathogenesis of airway and lung diseases such as chronic obstructive pulmonary disease (COPD) using preclinical genetic mouse models and human biosamples. The goal of the lab is also to be able to confirm and translate the findings using biospecimens from the established and establishing cohort of human patients with various lung diseases.

    COPD is a composite entity that includes chronic bronchitis and emphysema, is a leading cause of death in the world, and is a disease that is in need of new treatments. One of the goal of our laboratory is to investigate the interaction between CS and respiratory virus infection in the pathogenesis of COPD and identify novel therapeutic targets for this respiratory disease. It has been long thought that the frequent respiratory infections in COPD patients are due to their depressed immune function. Our studies have revealed that CS-exposed hosts have an over-exaggerated immune reaction to viral infections. Frequent acute COPD exacerbations correlate with increased rate of disease progression and more loss of lung function in COPD especially if it is due to viral infections. Our studies have shown that CS exposure has an impressive ability to regulate the innate immunity in the lung after influenza virus and respiratory syncytial virus (RSV) infection. CS enhances the inflammation, alveolar destruction and airway fibrosis caused by influenza virus and RSV. These effects are mediated by type I interferon and RIG-like helicase antiviral innate immune pathway. CS exposure also results in the induction of interleukin-15 in the setting of these respiratory infections. We hypothesize that these novel mechanistic pathways may explain the heightened inflammatory response and worsening lung functions in COPD patients with multiple virally-induced exacerbations, and the chronic lung inflammation seen in stable COPD patients. We have also translated our findings by studying these immune mediators in patients infected with various respiratory viruses and have thus far collected >300 human biosamples.
    YCCI Scholar 2011

  • Waldemar Von Zedtwitz Professor of Comparative Medicine and of Immunobiology

    Vishwa Deep Dixit completed Bachelor and Master of Veterinary Sciences in HAU, Hisar India. He received German Academic Exchange Service fellowship to conduct PhD research in Germany. He completed PhD coursework in HAU and Research Work in University of Hannover in Year 2000. He conducted postdoctoral research training in NIH. He joined Pennington Biomedical Research Center as an Assistant Professor in 2006 and moved to Yale as Professor of Comparative Medicine and Immunobiology in 2013. Dixit’s research is focused on understanding the interactions between metabolic and immune systems with the goal to reveal molecular targets that can be harnessed to control inflammation and immune dysfunction as means to enhance the healthspan. The research in Dixit Laboratory is funded by the National Institutes of Health, Glenn Foundation for Aging Research and Cure for Alzheimer Foundation.

  • Associate Professor of Laboratory Medicine, Immunobiology, Immunology; Associate Chair of Research, Laboratory Medicine; Assistant Director of Clinical Pathology Residency Program

    Dr. Eisenbarth’s laboratory focuses on how dendritic cells, B cells and T cells interact to induce tailored adaptive immune responses. The work spans how this triad is operational in the spleen to transfused red blood cells (RBCs), in the lung to aeroallergens, and in the gut to food allergens, utilizing both mouse models and human samples.

    https://eisenbarthlab.com/

  • Waldemar Von Zedtwitz Professor of Medicine (Infectious Diseases) and Professor of Epidemiology (Microbial Diseases) and of Microbial Pathogenesis; Section Chief, Infectious Diseases

    My laboratory investigates vector-borne diseases. Studies are directed toward understanding Lyme disease, Human granulocytic ehrlichiosis, and West Nile virus. Efforts on Lyme disease include exploring immunity to Borrelia burgdorferi, selective B. burgdorferi gene expression in vivo, and the immunobiology of Lyme arthritis. Human granulocytic ehrlichiosis is caused by a newly described pathogen, transmitted by Ixodes scapularis ticks, that persists within neutrophils. We are investigating the molecular strategies that this pathogen uses to survive in polymorphonuclear leukocytes. West Nile virus can cause fatal encephalitis, and we seek to understand the pathogenesis of this emerging disease. Finally, we are also developing molecular approaches to prevent ticks from feeding on a mammalian host, thereby interfering with pathogen transmission.

  • Sterling Professor of Immunobiology; Investigator, Howard Hughes Medical Institute

    Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the National Academy of Medicine. Richard Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.

  • Assistant Professor of Laboratory Medicine and Immunobiology

    Dr. Ellen Foxman, M.D., PhD. is an Assistant Professor of Laboratory Medicine and Immunobiology at the Yale School of Medicine. Her laboratory studies the fundamental biology of the airway epithelial development and innate immune signaling, and implications for the diagnosis and prevention of viral respiratory illness. 

    Background. Dr. Foxman is an immunologist and clinical pathologist. She trained in medicine and immunology at Stanford University.  In Dr. Eugene Butcher’s group, she investigated leukocyte homing and the role of short term memory of prior chemotactic signals in allowing neutrophils to reach their target sites within tissues.   She became interested in respiratory viruses during her residency training in clinical pathology at Harvard's Brigham and Women's Hospital, due to the advances in testing that were beginning to reveal a previously unappreciated very high prevalence of these viruses.  She later joined Dr. Akiko Iwasaki’s group at Yale as a post-doctoral associate, where she studied antiviral innate immunity, demonstrating suppression of innate immune responses in the airway epithelium by cool ambient temperature.  In 2016, she established her independent research group studying host-virus interactions in the respiratory tract.

  • William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology; Chair, Department of Neurology; Neurologist-in-Chief, Yale New Haven Hospital

    Dr. Hafler is the William S. and Lois Stiles Edgerly Professor and Chairman Department of Neurology, Yale School of Medicine and is the Neurologist-in-Chief of the Yale-New Haven Hospital. He graduated magna cum laude in 1974 from Emory University with combined B.S. and M.Sc. degrees in biochemistry, and the University of Miami School of Medicine in 1978. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York.

    Dr. Hafler received training in immunology at the Rockefeller University then at Harvard where he joined the faculty in 1984. He was one of the Executive Directors of the Program in Immunology at Harvard Medical School and was on the faculty of the Harvard-MIT Health Science and Technology program where he was actively involved in the training of graduate students and post-doctoral fellows.

    Hafler, in many respects, is credited with identifying the central mechanisms underlying the likely cause of MS. His early seminal work demonstrated that the disease began in the blood, not the brain, which eventually led to the development of Tysabri to treat the disease by blocking the movement of immune cells from the blood to the brain. He was the first to identify myelin-reactive T cells in the disease, published in Nature, showing that indeed, MS was an autoimmune disorder. He then went on to show why autoreactive T cells were dysregulated by the first identification of regulatory T cells in humans followed by demonstration of their dysfunctional state in MS. As a founding, Broad Institute associate member, Hafler identified the genes that cause MS, published in the New England Journal of Medicine and Nature. More recently, he identified the key transcription factors and signaling pathways associated with MS genes as potential treatment targets. Finally, he recently discovered that salt drives induction of these pathogenic myelin reactive T cells, both works published in Nature. Hafler was the Breakstone Professor of Neuroscience at Harvard, and became Chairman of Neurology at Yale in 2009, where he has built an outstanding clinical and research program that strongly integrates medical sciences. Hafler is among the most highly cited living neurologists and has received numerous honors including the Dystel Prize from the AAN for his MS research, the Raymond Adams Award from the ANA, and was the recipient of the NIH Javits Investigator Award, and The Dale McFarlin Prize by the International Society of Neuroimmunology. He is a member of AOA, the American Society of Clinical Investigation, and was elected into the National Academy of Medicine.

  • C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)

    My background and research are in translational immunology. I am interested in understanding the basis for autoimmune diseases and developing new therapies based on our understanding of disease mechanisms. My focus has largely been in the field of autoimmune Type 1 diabetes. The work encompasses basic laboratory work as well as clinical studies to understanding the regulation of autoreactive T cells to clinical trials that involve novel therapeutics. As part of these studies I have also been very interested in analysis of beta cell function in Type 1 diabetes. As part of this interest, we have been studying the development of autoimmune diabetes in patients with cancers who are treated with checkpoint inhibitors. Our clinical and basic studies are focused on understanding how beta cells are destroyed and react to inflammation. Finally, with the COVID-19 pandemic, we have been studying the immunologic basis for responses in children and adults who are hospitalized with COVID-19 to understand the mechanisms that can lead to disease protection. 

  • Associate Professor Term

    Dr. Ho takes molecular virology, immunology, and single-cell and genomics approaches to examine HIV persistence and HIV-induced immune dysfunction. Using clinical samples from HIV-infected individuals, the Ho lab investigates host-HIV interactions with particular interests in HIV-host RNA landscape (using single-cell RNAseq), CD4 T cell expansion dynamics, HIV-host genome interactions, and HIV-specific silencing, and immune escape mechanisms. Dr. Ho was a board-certified infectious disease attending physician in Taiwan. She received her PhD (2013) and postdoctoral training at Johns Hopkins University School of Medicine in Dr. Robert F. Siliciano's lab. She developed the first near-full-length single genome HIV proviral profiling (Cell 2013), identified defective HIV proviruses as a source of chronic immune activation in virally suppressed HIV-infected individuals (Cell Host Microbe 2017), and identified HIV-driven aberrant cancer gene expression as a mechanism of HIV persistence (Science Translational Medicine 2020). The Ho lab has active collaborations with physicians, immunologists, computer scientists, and HIV investigators both within Yale and in NIH-funded multi-center collaborations.

  • Waldemar Von Zedtwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology and Professor of Epidemiology (Microbial Diseases); Professor of Molecular Cellular and Developmental Biology; Investigator, Howard Hughes Medical Institute

    Akiko Iwasaki received her Ph.D. from the University of Toronto (Canada) in 1998, and her postdoctoral training from the National Institutes of Health (USA) (1998-2000). She joined Yale University (USA) as a faculty in 2000, and currently is an Investigator of the HHMI and Waldemar Von Zedtwitz Professor of Department of Immunobiology, and of Department of Molecular Cellular and Developmental Biology. Akiko Iwasaki’s research focuses on the mechanisms of immune defense against viruses at the mucosal surfaces. Her laboratory is interested in how innate recognition of viral infections lead to the generation of adaptive immunity, and how adaptive immunity mediates protection against subsequent viral challenge.

  • Assistant Professor

    I am a physician-scientist in the Section of Cardiovascular Medicine. My research laboratory studies the role of endothelial cells, the cells that line blood vessels, in solid organ transplant rejection. In this endeavor, we have developed novel, patient-centered protocols heavily incorporating human biospecimens to increase the likelihood that findings derived from these assays will be clinically relevant.